32.50
-0.245(-0.75%)
Currency In USD
Address
221 Crescent Street
Waltham, MA 02453
United States of America
Phone
617 272 4600
Sector
Healthcare
Industry
Biotechnology
Employees
143
First IPO Date
January 29, 2018
| Name | Title | Pay | Year Born |
| Stephen F. Mahoney | Chief Executive Officer, President & Director | 652,704 | 1971 |
| Thomas W. Beetham | Chief Operating Officer | 517,000 | 1970 |
| Seth Harmon | Chief Financial Officer | 552,467 | 1980 |
| Jennifer Tousignant | Chief Legal Officer | 611,951 | 1972 |
| Eric N. Olson | Co-Founder & Chairman of Scientific Advisory Board | 0 | N/A |
| Marvin H. Caruthers | Co-Founder & Scientific Advisory Board Member | 0 | 1940 |
| Michael R. Bristow | Co-Founder & Member of the Scientific Advisory Board | 0 | 1945 |
| Anthony Casciano | Chief Commercial Officer | 0 | 1977 |
| Vahe Bedian | Co-Founder & Scientific Advisor | 0 | N/A |
| Melissa Manno | Chief Human Resources Officer | 0 | N/A |
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.
